Journal of Clinical Oncology · 2004 · 144 citations · 62 references
MedicineMolecular GeneticsOncologyMolecular OncologyOncogenesThoracic OncologyCancer BiomarkersCancer Survival AnalysisLung CancerMolecular Tumor ProfilingOncogenic Signaling PathwaysRas Family OncogenesDisease-specific SurvivalLung Cancer StagingMolecular Prognostic MarkersOncogenic Ras MutationsPrognostic Factors AnalysisPrognostic PredictionPrognostic VariablesTumor-specific Biomarkers
PURPOSE: To analyze the prognostic significance of six molecular biomarkers (death-associated protein kinase [DAPK] promoter methylation, interleukin-10 [IL-10] protein expression, cyclooxygenase-2 [COX-2] mRNA expression, human telomerase reverse transcriptase catalytic subunit [hTERT] mRNA expression, retinoic acid receptor-beta [RAR-beta] mRNA expression, and K-ras mutational status) in stage I non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Biomarker analyses were performed on tumors from 94 patients with stage I NSCLC who underwent surgical resection at our institution. A minimum follow-up period of 5 years was required. DAPK methylation was assessed by methylation-specific polymerase chain reaction (PCR). RAR-beta, COX-2, and hTERT mRNA levels were determined by in situ hybridization with digoxigenin-labeled antisense riboprobes. K-ras mutation status was determined by the PCR-primer introduced restriction with enrichment for mutant alleles method. IL-10 protein expression was analyzed by immunohistochemistry using a polyclonal antihuman IL-10 antibody. Cancer-specific survival was analyzed with a Cox proportional hazards model. To identify independent prognostic factors, a stepwise selection method was used. RESULTS: DAPK methylation, IL-10 lack of expression, COX-2 expression, hTERT expression, RAR-beta expression, and K-ras mutations were observed in 46.8%, 29.8%, 59.6%, 34.0%, 23.4%, and 34.0% of patients, respectively. In the final model, DAPK methylation and IL-10 lack of expression were significant negative prognostic factors for cancer-specific survival, whereas COX-2 expression was of borderline significance. CONCLUSION: In this cohort of resected stage I NSCLC patients, molecular markers that independently predict cancer-specific survival have been identified. The prognostic roles of DAPK methylation, IL-10, and other biomarkers in NSCLC merit further investigation.
62
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Nam W. Kim, Mieczyslaw A. Piatyszek, Karen R. Prowse et al. · Science · 1994 · 7.1K citations
Revisions in the International System for Staging Lung Cancer
Clifton F. Mountain · CHEST Journal · 1997 · 4.6K citations
Ahmedin Jemal, Thomas S. Murray, Alicia Samuels et al. · CA A Cancer Journal for Clinicians · 2003 · 3.3K citations · Full text
Medicine, Demography, Oncology +17
Gene-expression profiles predict survival of patients with lung adenocarcinoma
David G. Beer, Sharon L. R. Kardia, Chiang‐Ching Huang et al. · Nature Medicine · 2002 · 2.1K citations
A gene hypermethylation profile of human cancer.
Manel Esteller, Paul G. Corn, Stephen B. Baylin et al. · PubMed · 2001 · 2K citations